- Title Postdoctoral Associate – Mikel Garcia-Marcos Lab
- Education M.Sc. Università degli Studi di Milano-Bicocca (Milan, Italy)
Ph.D. from the University of Montpellier (Montpellier, France)
- Office K2
- Email firstname.lastname@example.org
- Area of Interest G protein signaling
I am currently a Postdoctoral Associate in the laboratory of Dr. Mikel Garcia-Marcos in the Department of Biochemistry at Boston University School of Medicine. During my Ph.D., I worked on the metabotropic glutamate receptor 2 (mGluR2). This G protein-coupled receptor (GPCR) keeps on attracting particular attention given its implication in schizophrenia, a multifactorial psychiatric disease. mGluR2 is the main target of a new generation of antipsychotics currently under clinical trial that are currently the most efficient and promising antipsychotics ever seen. However, mGluR2 signaling remain poorly characterized. During my Ph.D., I have taken advantage of a nanobody specifically targeting endogenous mGluR2. From mass spectrometry to animal behavioral test, I was able to fully decipher the first non-canonical signaling pathway of mGluR2: TrkB, a tyrosine receptor kinase that plays a key role in mediating the antipsychotics effect of the new generation of antipsychotics. My current research now in Dr. Mikel Garcia-Marcos’ lab will focus, on one hand, on generating new rationally engineered protein that will help to better understand G-protein signaling pathway and, on the other hand, characterizing the importance of a G-protein regulator in the brain.
Brenner D, Sieverding K, Bruno C, Lüningschrör P, Buck E, Mungwa S, Fischer L, Brockmann SJ, Ulmer J, Bliederhäuser C, Philibert CE, Satoh T, Akira S, Boillée S, Mayer B, Sendtner M, Ludolph AC, Danzer KM, Lobsiger CS, Freischmidt A, Weishaupt JH. Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice. J Exp Med. 2019 Feb 4;216(2):267-278. doi: 10.1084/jem.20180729. Epub 2019 Jan 11. PMID: 30635357; PMCID: PMC6363427.